Search | TVST | ARVO Journals

Showing 1 – 20 of 25

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina May 2025

Functional Vision Assessment Over 4 Years in USH2A Using the Veteran Affairs Low-Vision Visual Functioning Questionnaire

PDF

Bela Parekh; Nicholas Peck-Dimit; Jacque L. Duncan; Lassana Samarakoon; Maria Fernanda Abalem; Chris A. Andrews; Isabelle Audo; Allison R. Ayala; Chris Bradley; Janet K. Cheetham; Gislin Dagnelie; Todd A. Durham; Rachel M. Huckfeldt; Gabrielle D. Lacy; Brett Malbin; Michel Michaelides; David C. Musch; Katarina Stingl; Christina Y. Weng; Alex Z. Zmejkoski; Michele Melia; K. Thiran Jayasundera; for the Foundation Fighting Blindness Clinical Consortium Investigator Group
TAGS: blindness, cohort studies, questionnaires, veterans, vision, vision tests, visual impairment
Invest. Ophthalmol. Vis. Sci.. 2025; 66(5):39. https://doi.org/10.1167/iovs.66.5.39

Includes: Supplemental Content

Genetics February 2025

Characterizing the Genetic Basis for Inherited Retinal Disease: Lessons Learned From the Foundation Fighting Blindness Clinical Consortium's Gene Poll

PDF

Kari Branham; Lassana Samarakoon; Isabelle Audo; Allison R. Ayala; Janet K. Cheetham; Stephen P. Daiger; Patty Dhooge; Jacque L. Duncan; Todd A. Durham; Abigail T. Fahim; Rachel M. Huckfeldt; Robert B. Hufnagel; Susanne Kohl; Ramiro S. Maldonado; Michele Melia; Michel Michaelides; Mark E. Pennesi; José-Alain Sahel; Juliana M. Ferraz Sallum; Mandeep S. Singh; Dror Sharon; Kimberly Stepien; Kaylie Jones; Christina Y. Weng; for the Foundation Fighting Blindness Clinical Consortium Investigator Group
TAGS: blindness, genes, genetics, retinal diseases, social survey
Invest. Ophthalmol. Vis. Sci.. 2025; 66(2):12. https://doi.org/10.1167/iovs.66.2.12

Includes: Supplemental Content

Retina October 2024

Endpoints and Design for Clinical Trials in USH2A -Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study

PDF

Maureen G. Maguire; David G. Birch; Jacque L. Duncan; Allison R. Ayala; Lauren N. Ayton; Janet K. Cheetham; Peiyao Cheng; Todd A. Durham; Frederick L. Ferris, III; Carel B. Hoyng; Rachel M. Huckfeldt; Glenn J. Jaffe; Christine Kay; Eleonora M. Lad; Bart P. Leroy; Wendi Liang; Lee S. McDaniel; Michele Melia; Michel Michaelides; Mark E. Pennesi; José-Alain Sahel; Lassana Samarakoon; on behalf of the REDI Working Group and the Foundation Fighting Blindness Clinical Consortium Investigator Group
TAGS: cohort studies, eye, natural history, outcome measures, retinal degeneration, sample size, surrogate endpoints, vision, united states food and drug administration, perimetry
Trans. Vis. Sci. Tech.. 2024; 13(10):15. https://doi.org/10.1167/tvst.13.10.15

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2024

A multicenter, open-labeled, phase 2a study of AG-73305, a novel bi-specific Fc-fusion protein for the treatment of diabetic macular edema

Tan Nguyen; Sunil Patel; Janet K Cheetham; David S Boyer; Artemis Wu; Larry A Wheeler; Madhu Cherukury

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1759.

ARVO Annual Meeting Abstract June 2024

AG-80308, a novel first-in-class ophthalmic solution for the treatment of dry eye disease

Janet K Cheetham; Sandy Lai; Tan Nguyen; Sunil S Patel; Scott M Whitcup; Madhu Cherukury

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2984.

Retina June 2024

Self-Reported Functional Vision in USH2A -Associated Retinal Degeneration as Measured by the Michigan Retinal Degeneration Questionnaire

PDF

Bela Parekh; Jacque L. Duncan; Lassana Samarakoon; Michele Melia; Maria Fernanda Abalem; Chris A. Andrews; Isabelle Audo; Allison R. Ayala; Chris Bradley; Janet K. Cheetham; Gislin Dagnelie; Todd A. Durham; Rachel M. Huckfeldt; Gabrielle D. Lacy; Brett Malbin; Michel Michaelides; David C. Musch; Nicholas Peck-Dimit; Katarina Stingl; Christina Y. Weng; Alex Z. Zmejkoski; K. Thiran Jayasundera; for the Foundation Fighting Blindness Clinical Consortium Investigator Group
TAGS: michigan, questionnaires, retinal degeneration, self-report, vision, vision tests
Invest. Ophthalmol. Vis. Sci.. 2024; 65(6):5. https://doi.org/10.1167/iovs.65.6.5

Includes: Supplemental Content

Perspective June 2023

Overcoming the Challenges to Clinical Development of X-Linked Retinitis Pigmentosa Therapies: Proceedings of an Expert Panel

PDF

David G. Birch; Janet K. Cheetham; Stephen P. Daiger; Carel Hoyng; Christine Kay; Ian M. MacDonald; Mark E. Pennesi; Lori S. Sullivan
TAGS: gene therapy, mutation, natural history, phenotype, retinitis pigmentosa, x-linked inheritance, disease progression, blindness, retinal diseases, surrogate endpoints
Trans. Vis. Sci. Tech.. 2023; 12(6):5. https://doi.org/10.1167/tvst.12.6.5

ARVO Annual Meeting Abstract June 2023

Open-label Phase 2a study of AG-73305, a novel bi-specific Fc-fusion protein for the treatment of diabetic macular edema

Sunil Patel; Janet K Cheetham; Tan Nguyen; David S Boyer; Artemis Wu; Ben Chang; Larry A Wheeler; Madhu Cherukury

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2642.

ARVO Annual Meeting Abstract June 2022

Visual acuity and full-field stimulus thresholds (FST) over 2 years in the RUSH2A study: annual rates of change from mixed effects modeling

Peiyao Cheng; David G Birch; Jacque L Duncan; Frederick L Ferris; Maureen G Maguire; Allison R. Ayala; Janet K Cheetham; Todd Durham; Abigail T Fahim; Rachel M Huckfeldt; Michel Michaelides; Mark E Pennesi; Jose Alain Sahel; Katarina Stingl; Ajoy Vincent; Christina Y Weng

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4480 – F0267.

Retina March 2022

The RUSH2A Study: Dark-Adapted Visual Fields in Patients With Retinal Degeneration Associated With Biallelic Variants in the USH2A Gene

PDF

David G. Birch; Lassana Samarakoon; Michele Melia; Jacque L. Duncan; Allison R. Ayala; Isabelle Audo; Janet K. Cheetham; Todd A. Durham; Alessandro Iannaccone; Mark E. Pennesi; Katarina Stingl; for the Foundation Fighting Blindness Consortium Investigator Group
TAGS: genes, retinal degeneration, rod photoreceptors, visual fields, illness length
Invest. Ophthalmol. Vis. Sci.. 2022; 63(3):17. https://doi.org/10.1167/iovs.63.3.17

ARVO Annual Meeting Abstract June 2021

Auditory and olfactory findings from the Rate of Progression of USH2A -related Retinal Degeneration (RUSH2A) study

Alessandro Iannaccone; Carmen C. Brewer; Peiyao Cheng; Jacque L Duncan; Maureen G Maguire; Isabelle Audo; Allison Ayala; Paul S Bernstein; Gavin M. bidelman; Janet K Cheetham; Richard L. Doty; Todd Durham; Robert B Hufnagel; Mark H. Myers; Wadih M Zein

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1537.

ARVO Annual Meeting Abstract June 2021

Patient-reported visual functioning in persons with bi-allelic USH2A variants

Elise Heon; B. Michele Melia; Laura E Bocchino; Jacque L Duncan; Allison Ayala; Chris Bradley; Isabelle Audo; Janet K Cheetham; Gislin Dagnelie; Todd Durham; Carel Hoyng; Nieraj Jain; Thiran Jayasundera; Mark E Pennesi; Christina Y Weng

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3541.

ARVO Annual Meeting Abstract June 2021

Dark-adapted visual fields (DAVF) in patients with two disease-causing variants in USH2A

David G Birch; Lassana Samarakoon; Laura E Bocchino; B. Michele Melia; Jacque L Duncan; Allison Ayala; Isabelle Audo; Janet K Cheetham; Todd Durham; Alessandro Iannaccone; Mark E Pennesi; Katarina Stingl

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3241.

Perspective April 2021

Tackling the Challenges of Product Development Through a Collaborative Rare Disease Network: The Foundation Fighting Blindness Consortium

PDF

Todd A. Durham; Jacque L. Duncan; Allison R. Ayala; David G. Birch; Janet K. Cheetham; Frederick L. Ferris, III; Carel B. Hoyng; Mark E. Pennesi; José-Alain Sahel; for the Foundation Fighting Blindness Consortium Investigator Group
TAGS: blindness, rare diseases
Trans. Vis. Sci. Tech.. 2021; 10(4):23. https://doi.org/10.1167/tvst.10.4.23

Articles October 2020

The RUSH2A Study: Best-Corrected Visual Acuity, Full-Field Electroretinography Amplitudes, and Full-Field Stimulus Thresholds at Baseline

PDF

David G. Birch; Peiyao Cheng; Jacque L. Duncan; Allison R. Ayala; Maureen G. Maguire; Isabelle Audo; Janet K. Cheetham; Todd A. Durham; Abigail T. Fahim; Frederick L. Ferris, III; Elise Heon; Rachel M. Huckfeldt; Alessandro Iannaccone; Naheed W. Khan; Eleonora M. Lad; Michel Michaelides; Mark E. Pennesi; Katarina Stingl; Ajoy Vincent; Christina Y. Weng; for the Foundation Fighting Blindness Consortium Investigator Group
TAGS: electroretinography, visual acuity
Trans. Vis. Sci. Tech.. 2020; 9(11):9. https://doi.org/10.1167/tvst.9.11.9

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2020

Accelerating research in rare inherited retinal disorders (IRDs) through an international consortium

Janet K Cheetham; Allison Ayala; David G Birch; Jacque L Duncan; Todd Durham; Frederick L Ferris; Maureen Maguire; Mark E Pennesi

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3356.

ARVO Annual Meeting Abstract June 2020

Baseline visual fields in the RUSH2A study: Associated factors and correlation with measures of disease severity

Jacque L Duncan; Wendi Liang; Isabelle S Audo; David G Birch; Joseph Carroll; Janet K. Cheetham; Laura R Erker; Frederick L Ferris; Elise Heon; Robert Hufnagel; Alessandro Iannaccone; Glenn J Jaffe; Christine N Kay; Maureen Maguire; Michel Michaelides; Mark E Pennesi

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3364.

ARVO Annual Meeting Abstract June 2020

Test-retest variability of static perimetry and microperimetry results from the RUSH2A study

Allison Ayala; Wendi Liang; David G Birch; Janet K Cheetham; Elvira N Chegarnov; Jacque L Duncan; Todd Durham; Frederick L Ferris; Eleonora M Lad; Maureen Maguire; Mark E Pennesi

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3342.

ARVO Annual Meeting Abstract July 2019

Using retinal structural measurements derived from optical coherence tomography as clinical endpoints for Stargardt disease - reproducibility assessment and lessons learned from the ProgStar study

Xiangrong Kong; Alexander Ho; Beatriz Munoz; Sheila K West; Rupert W Strauss; Anamika Jha; Ann Margret Ervin; Janet Cheetham; Michael S Ip; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3945.

Articles June 2019

Reproducibility of Measurements of Retinal Structural Parameters Using Optical Coherence Tomography in Stargardt Disease

PDF

Xiangrong Kong; Alexander Ho; Beatriz Munoz; Sheila West; Rupert W. Strauss; Anamika Jha; Ann Ervin; Jeff Buzas; Mandeep Singh; Zhihong Hu; Janet Cheetham; Michael Ip; Hendrik P. N. Scholl
TAGS: optical coherence tomography, retina, spectral domain-optical coherence tomography, stargardt's disease, atrophy, eye, surrogate endpoints
Trans. Vis. Sci. Tech.. 2019; 8(3):46. https://doi.org/10.1167/tvst.8.3.46

Includes: Supplemental Content

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Functional Vision Assessment Over 4 Years in USH2A Using the Veteran Affairs Low-Vision Visual Functioning Questionnaire

Characterizing the Genetic Basis for Inherited Retinal Disease: Lessons Learned From the Foundation Fighting Blindness Clinical Consortium's Gene Poll

Endpoints and Design for Clinical Trials in USH2A -Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study

A multicenter, open-labeled, phase 2a study of AG-73305, a novel bi-specific Fc-fusion protein for the treatment of diabetic macular edema

AG-80308, a novel first-in-class ophthalmic solution for the treatment of dry eye disease

Self-Reported Functional Vision in USH2A -Associated Retinal Degeneration as Measured by the Michigan Retinal Degeneration Questionnaire

Overcoming the Challenges to Clinical Development of X-Linked Retinitis Pigmentosa Therapies: Proceedings of an Expert Panel

Open-label Phase 2a study of AG-73305, a novel bi-specific Fc-fusion protein for the treatment of diabetic macular edema

Visual acuity and full-field stimulus thresholds (FST) over 2 years in the RUSH2A study: annual rates of change from mixed effects modeling

The RUSH2A Study: Dark-Adapted Visual Fields in Patients With Retinal Degeneration Associated With Biallelic Variants in the USH2A Gene

Auditory and olfactory findings from the Rate of Progression of USH2A -related Retinal Degeneration (RUSH2A) study

Patient-reported visual functioning in persons with bi-allelic USH2A variants

Dark-adapted visual fields (DAVF) in patients with two disease-causing variants in USH2A

Tackling the Challenges of Product Development Through a Collaborative Rare Disease Network: The Foundation Fighting Blindness Consortium

The RUSH2A Study: Best-Corrected Visual Acuity, Full-Field Electroretinography Amplitudes, and Full-Field Stimulus Thresholds at Baseline

Accelerating research in rare inherited retinal disorders (IRDs) through an international consortium

Baseline visual fields in the RUSH2A study: Associated factors and correlation with measures of disease severity

Test-retest variability of static perimetry and microperimetry results from the RUSH2A study

Using retinal structural measurements derived from optical coherence tomography as clinical endpoints for Stargardt disease - reproducibility assessment and lessons learned from the ProgStar study

Reproducibility of Measurements of Retinal Structural Parameters Using Optical Coherence Tomography in Stargardt Disease

To View More...

You must be signed into an individual account to use this feature.